POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride replenishes intracellular potassium; dextrose provides caloric energy; sodium chloride maintains extracellular fluid osmolality. The combination corrects fluid, electrolyte, and caloric deficits.
| Metabolism | Dextrose is metabolized via glycolysis and the citric acid cycle; sodium and potassium are excreted primarily via kidneys; chloride follows sodium and potassium handling. |
| Excretion | Potassium: renal (90% excreted unchanged, primarily via distal tubule and collecting duct secretion; minor fecal loss ~10%). Dextrose: metabolized to CO2 and water (renal excretion of glucose negligible unless hyperglycemia exceeds renal threshold). Sodium: renal (95% excreted unchanged, regulated by aldosterone). Chloride: renal (primarily reabsorbed; excreted as counterion for ammonium or potassium). |
| Half-life | Potassium: rapid redistribution half-life ~0.5-1 hour; terminal elimination half-life ~2-4 hours, dependent on renal function and total body potassium stores. Dextrose: negligible (rapidly metabolized; half-life <15 minutes). Sodium: 2-4 hours under normal regulation. Clinical context: half-lives are dose-independent and reflect body's homeostatic control. |
| Protein binding | Potassium: not bound (<1%); free ion. Dextrose: not bound. Sodium: negligible binding (<1%). Chloride: negligible binding. |
| Volume of Distribution | Potassium: 4-5 L/kg in total body water with intracellular accumulation (98% intracellular); apparent Vd for extracellular deficit ~0.5 L/kg. Dextrose: 0.2-0.3 L/kg (extracellular fluid). Sodium: ~0.15 L/kg (extracellular). Chloride: ~0.15 L/kg (extracellular). Clinical meaning: reflects extensive intracellular uptake for potassium; for others, limited to extracellular space. |
| Bioavailability | Intravenous: 100% for all components. Not administered orally as this formulation. Bioavailability not applicable for other routes. |
| Onset of Action | Intravenous: potassium effect on serum potassium levels begins within minutes (distribution phase); clinical effect (e.g., ECG normalization) occurs in 5-15 minutes. Dextrose: hyperglycemic effect within 2 minutes. Sodium/chloride: volume expansion effect within 1-2 minutes. |
| Duration of Action | Potassium: duration of serum elevation after IV infusion ~2-6 hours, depending on dose and renal function; ECG effects persist as long as hypokalemia corrected. Dextrose: plasma glucose elevation lasts 30-60 minutes post-infusion due to insulin-mediated uptake. Sodium/chloride: volume effect persists for 2-4 hours, with redistribution. |
| Molecular Weight | 74.55 |
Intravenous infusion: 0.3% KCl, 10% dextrose, 0.2% NaCl solution administered at 100-125 mL/hour (providing 3-3.75 mEq KCl/hour). Typical adult dose: 10-20 mEq KCl per hour via continuous infusion, not to exceed 20 mEq/hour or 200 mEq/day. Rate adjusted based on serum potassium and clinical response.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 30-50 mL/min: reduce infusion rate by 25-50% or monitor potassium closely. GFR < 30 mL/min: avoid use or use extreme caution due to risk of hyperkalemia; consider alternative potassium-sparing strategies. Maximum potassium infusion rate not established; clinical monitoring essential. |
| Liver impairment | No dosage adjustment based on Child-Pugh class. However, in severe hepatic impairment (Child-Pugh C), monitor for hyperkalemia due to potential concurrent renal dysfunction. |
| Pediatric use | Intravenous infusion: 0.3% KCl, 10% dextrose, 0.2% NaCl solution. Initial dose: 0.5-1 mEq/kg body weight per hour for severe hypokalemia. Maintenance: 2-3 mEq/kg per day as continuous infusion. Rate not to exceed 1 mEq/kg/hour. Carefully monitor serum potassium and ECG. |
| Geriatric use | Start at lower end of dosing range (e.g., initial infusion rate 50-100 mL/hour) due to age-related decline in renal function and increased risk of hyperkalemia. Monitor serum potassium and renal function frequently. Avoid in patients with severe renal impairment (GFR <30 mL/min). |
| 1st trimester | Potassium chloride, dextrose, and sodium chloride are essential electrolytes and nutrients. At typical replacement doses, no known teratogenic risk. Use only if clearly needed. |
| 2nd trimester | Safe for maternal electrolyte and fluid balance. Monitor serum potassium and glucose levels. |
| 3rd trimester | Use caution to avoid fluid overload and electrolyte imbalances, especially in preeclampsia or renal impairment. Adequate maternal hydration and electrolyte homeostasis are important. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium, glucose, and sodium readily cross the placenta via active transport and diffusion. Fetal serum levels equilibrate with maternal levels. No adverse effects at therapeutic doses. |
| Breastfeeding | Potassium, glucose, and sodium are normal constituents of breast milk. Administration of these IV solutions does not pose a risk to the infant. Excretion into milk is minimal and not clinically significant. |
| Lactation Rating | L1 – Safe |
| Teratogenic Risk | Potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No teratogenic risk is associated with their use at therapeutic doses. Excessive potassium may cause fetal hyperkalemia. Dextrose may cause fetal hyperglycemia and insulin response. Sodium chloride at excessive doses may cause fluid overload. No trimester-specific risks. |
| Fetal Monitoring | Monitor serum electrolytes (potassium, sodium, glucose), renal function, fluid balance, and urine output. Fetal monitoring for signs of hyperkalemia or hyperglycemia if maternal levels are high. |
| Fertility Effects | No known adverse effects on fertility. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions must be diluted before use to avoid fatal hyperkalemia. Additives may be incompatible.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHyperglycemiaHypernatremiaSevere renal impairment (oliguria, anuria)Addison's diseaseSevere dehydration with metabolic acidosisConditions causing intracellular potassium shift (e.g., digitalis toxicity, familial periodic paralysis)
| Precautions | Monitor serum potassium, sodium, glucose, and fluid balance; risk of hyperkalemia, especially in renal impairment; risk of hyperglycemia; extravasation risk; use with caution in heart failure, renal failure, and diabetes. |
| Food/Dietary | No specific food interactions with IV administration. Oral dietary potassium should be considered only under medical supervision to avoid hyperkalemia. |
| Clinical Pearls | This is a maintenance IV fluid containing potassium chloride (0.3% = 40 mEq/L), dextrose (10% = 100 g/L), and sodium chloride (0.2% = 34 mEq/L). Monitor serum potassium closely; do not infuse rapidly to avoid cardiac arrhythmias. Use with caution in renal impairment. Dextrose content may cause hyperglycemia; consider insulin coverage if needed. Ensure IV compatibility with other medications. |
| Patient Advice | This IV fluid contains potassium, which is important for heart and muscle function. · You will have regular blood tests to monitor your potassium levels. · Tell your nurse if you feel chest tightness, muscle weakness, or irregular heartbeat. · This fluid also contains sugar; if you have diabetes, your blood sugar will be monitored. |
Loading safety data…